Aglaia Management B.V.

About The Fund

Aglaia Management B.V, operating as Aglaia Oncology Funds, concentrates its investments in the domain of early-stage oncology drug development companies. With a track record since 2004, the firm is recognized as a pioneer in impact investing, with a specific focus on transforming cancer treatment. They have developed a monitoring tool in collaboration with Sinzer-Grant Thornton that evaluates the socio-economic impact of their investments in oncology biotech firms, underscoring a blend of financial returns with substantial impact on healthcare and society. Aglaia's team, possessing extensive experience in cancer research and oncology drug development, takes hands-on roles in guiding strategic directions and designing R&D plans, covering the spectrum from early screening to clinical studies. They have launched multiple Oncology Funds, contributing to the advancement and success of over 100 oncology products and transitioning early-stage companies to more mature stages, making them attractive for licensing, acquisitions, or IPOs. Aglaia embodies the ethos of the Greek goddess of beauty and good health, aiming to enhance wellbeing by developing innovative cancer therapies that offer higher cure rates and fewer side effects. The firm is not currently looking for new investment opportunities; however, their criteria for previous investments included early-stage oncology development, disruptive science with the potential to transform care, diverse drug modalities, and inventions predicted to be more effective than standard care upon market entry. They emphasize the importance of rigorous preclinical validation and patentability of inventions. Additionally, Aglaia takes a disciplined approach to financing and operational management to maximize value creation and efficiency, looking for team members who bring diverse expertise. They also have a dedicated Life Sciences Impact Suite that monitors the socio-economic performance of investments and advances a patient-centric culture in the industry.